[Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease].
OBJECTIVE
The present study describes two patients with retroperitoneal fibrosis following prolonged use of bromocriptine and pergolide for Parkinson's disease. Both patients also presented severe atheromatosis.


METHODS
Similar cases reported in the literature are reviewed and the possible relationship between the use of the ergotamine derivate and severe atheromatosis is discussed.


RESULTS
Both patients, a 67-year-old male and a 62-year-old female, improved after discontinuing bromocriptine, despite severe damage of renal function.


CONCLUSIONS
Retroperitoneal fibrosis may develop in patients with bilateral ureteral obstruction, especially those who have received drugs that have been reported to cause the foregoing condition.
Sánchez-Chapado
M
M
Servicio de Urología, Hospital Principe de Asturias, Facultad de Medicina, Universidad de Alcalá de Henares, Madrid.
Angulo Cuesta
J
J
Guil Cid
M
M
Jiménez
F J
FJ
López Alvarez
Y J
YJ
D000368:Aged; D001971:Bromocriptine / Q000009:adverse effects*; D018491:Dopamine Agonists / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy; D010479:Pergolide / Q000009:adverse effects*; D012185:Retroperitoneal Fibrosis / Q000139:chemically induced*
D018491:Dopamine Agonists; D010479:Pergolide; D001971:Bromocriptine